Get started
Author

Ida Paris

Observed names: I Paris, I. Paris, Paris Ida, Paris, Ida
Observed institutions: Università Cattolica del Sacro Cuore, University of Verona, Università Campus Bio-Medico, University of L'Aquila, Policlinico Umberto I, Agostino Gemelli University Polyclinic, Fatebenefratelli Hospital, Azienda Ospedaliero-Universitaria di Modena, Azienda Ospedaliera Sant'Andrea, Ospedale di Belcolle, IRCCS Ospedale San Raffaele, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Ospedale Vito Fazzi, Istituti di Ricovero e Cura a Carattere Scientifico, Instituto Nazionale Tumori Regina Elena, University of Naples Federico II, Sapienza University of Rome
ORCID: 0000-0002-7445-3366
Observed ORCID: 0000-0002-7445-3366
OpenAlex ID: A5032805474
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01
2024 · Aditya Bardia, Komal Jhaveri, et al. · Journal of Clinical Oncology · 204
PDF
Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives
2019 · Luisa Carbognin, Federica Miglietta, et al. · Cancers · 120
PDF
Overall Survival of CDK4/6-Inhibitor–Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis
2020 · Francesco Schettini, Fabiola Giudici, et al. · JNCI Journal of the National Cancer Institute · 104
PDF
BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study
2017 · Marco Petrillo, Claudia Marchetti, et al. · American Journal of Obstetrics and Gynecology · 89
Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis
2024 · Roberta Caputo, Giuseppe Buono, et al. · Frontiers in Oncology · 78
PDF
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
2020 · Giulia Bon, Laura Pizzuti, et al. · Journal of Experimental & Clinical Cancer Research · 74
PDF
CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives
2021 · Michela Roberto, Antonio Astone, et al. · Cancers · 66
PDF
Pregnancy After Breast Cancer in Young BRCA Carriers
2023 · Matteo Lambertini, Eva Blondeaux, et al. · JAMA · 64
PDF
Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis
2021 · Francesco Schettini, Fabiola Giudici, et al. · European Journal of Cancer · 63
PDF
Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors
2020 · Giovanna Garufi, Antonella Palazzo, et al. · Expert Opinion on Pharmacotherapy · 61
Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: A pilot study
2009 · A. Fagotti, I. Paris, et al. · Gynecologic Oncology · 61
T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer
2018 · Alessandra Fabi, Daniele Alesini, et al. · The Breast · 60
Ultrasound morphometric and cytologic preoperative assessment of inguinal lymph‐node status in women with vulvar cancer: MorphoNode study
2019 · G. Garganese, S. M. Fragomeni, et al. · Ultrasound in Obstetrics and Gynecology · 53
PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives
2022 · Paola Fuso, Margherita Muratore, et al. · Cancers · 52
PDF
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study
2023 · Andrea Botticelli, Roberta Caputo, et al. · The Oncologist · 44
PDF
BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making
2022 · Francesco Pavese, Ettore Domenico Capoluongo, et al. · Cancers · 44
PDF
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
2021 · Laura Pizzuti, Maddalena Barba, et al. · Scientific Reports · 42
Pregnancy-Associated Breast Cancer: A Multidisciplinary Approach
2020 · Ida Paris, Danilo Di Giorgio, et al. · Clinical Breast Cancer · 42
Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: Updated results and long-term survival
2005 · Gabriella Ferrandina, Ida Paris, et al. · Gynecologic Oncology · 41
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study
2018 · Teresa Gamucci, Laura Pizzuti, et al. · Cancer Biology & Therapy · 39
PDF
Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study
2015 · Marco Petrillo, Ida Paris, et al. · Annals of Surgical Oncology · 37
A Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of 5-Fluorouracil Degradation Rate by Intact Peripheral Blood Mononuclear Cells
2009 · Alfonso M Lostia, Luana Lionetto, et al. · Therapeutic Drug Monitoring · 37
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer
2022 · Francesco Schettini, Sergio Venturini, et al. · Cancer Treatment Reviews · 36
PDF
Palliative electrochemotherapy in primary or recurrent vulvar cancer
2020 · Giacomo Corrado, Giuseppe Cutillo, et al. · International Journal of Gynecological Cancer · 33
Upfront HIPEC and bevacizumab-containing adjuvant chemotherapy in advanced epithelial ovarian cancer
2018 · Ida Paris, Stefano Cianci, et al. · International Journal of Hyperthermia · 33
PDF
Works count: 197
Citation count: 2,495
H-index: 29
I10-index: 63
Year
Topic
Type